To further study these three putative erlotinib‐sensitizing chemicals (SJ‐172550, nutlin‐3, and carfilzomib), we performed efficacy testing with a human lung cancer PDX model having an EGFR T790M mutation (i.e., comprised of erlotinib‐resistant cells). This evidence concerns the gene EGFR and lung carcinoma.